Fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, 59, boulevard Pinel, 69677 Lyon, France.
Service de biostatistique et bioinformatique, hospices civils de Lyon, 69003 Lyon, France; Université de Lyon, 69000 Lyon, France; Université Lyon 1, 69100 Villeurbanne, France; CNRS, UMR 5558, laboratoire de biométrie et biologie évolutive, équipe biostatistique-santé, 69100 Villeurbanne, France.
Ann Endocrinol (Paris). 2019 Feb;80(1):32-37. doi: 10.1016/j.ando.2018.01.002. Epub 2018 Sep 19.
Bilateral adrenalectomy (BADX) has become an important treatment of Cushing's disease (CD), especially when other treatment options have failed. The aim of this study was to evaluate the long-term quality of life (QoL) of patients having undergone BADX for CD, in comparison to other therapeutic options.
Thirty-four patients with CD were identified in two French centers: 17 underwent BADX and the remaining 17 one or more of the following treatments: surgery, medical therapy or radiotherapy. Three questionnaires were filled in by each patient in order to evaluate their QoL: Short Form-36 Health Survey (SF-36), Cushing QoL questionnaire and Beck depression inventory (BDI).
The mean age of patients was 49.3±15.2 years. Average time lapse between diagnosis and BADX was 6.1 years. Results from each questionnaire adjusted to age showed a lower QoL among patients who underwent BADX. These were significant in most aspects of the SF-36 questionnaire (bodily pain P<0.01, general health P<0.01, vitality P≤0.05, social functioning P≤0.05), as well as in the Cushing QoL questionnaire (P<0.05) and BDI (P≤0.05). Adrenal insufficiency appeared to be the major predictor of poor QoL whatever their initial treatment.
Despite their clinical remission, patients who undergo BADX appear to be at a greater risk of suffering an impaired QoL due to more prolonged period of time with imperfectly controlled hypercortisolism combined with definitive adrenal insufficiency.
双侧肾上腺切除术(BADX)已成为库欣病(CD)的重要治疗方法,尤其是在其他治疗选择失败时。本研究旨在评估因 CD 而行 BADX 的患者与其他治疗选择相比的长期生活质量(QoL)。
在法国的两个中心确定了 34 名 CD 患者:17 名患者接受了 BADX,其余 17 名患者接受了以下一种或多种治疗:手术、药物治疗或放射治疗。每位患者填写了三个问卷,以评估他们的 QoL:健康调查简表 36 项(SF-36)、库欣 QoL 问卷和贝克抑郁量表(BDI)。
患者的平均年龄为 49.3±15.2 岁。从诊断到 BADX 的平均时间间隔为 6.1 年。调整年龄后的每个问卷的结果显示,接受 BADX 的患者 QoL 较低。SF-36 问卷的大多数方面(身体疼痛 P<0.01、一般健康 P<0.01、活力 P≤0.05、社会功能 P≤0.05)以及库欣 QoL 问卷(P<0.05)和 BDI(P≤0.05)都有显著差异。肾上腺功能不全似乎是 QoL 较差的主要预测因素,与初始治疗无关。
尽管临床缓解,接受 BADX 的患者似乎由于长时间未完全控制皮质醇增多症和永久性肾上腺功能不全而面临更高的 QoL 受损风险。